At the end of life, patients with cancer can continue to require intensive intervention to alleviate symptoms. When enrolled in hospice, however, they may find expensive treatment modalities, even those administered with palliative intent, inaccessible. This is because current reimbursement artificially divides the continuum of disease management into arbitrary phases of care: Medicare parts A, B and D for curative therapy and the Medicare Hospice Benefit for hospice care. The mechanism of reimbursement can disproportionately dictate availability and access to certain types of care. This is problematic because some treatment modalities (eg, diuretics for heart failure) can span both phases, and many palliative therapies have been empirically shown to improve quality of life and lengthen life.1 We use palliative radiotherapy as an example to illustrate some of the unintended consequences of this approach.
Perumalswami CR, Mullangi S, Jagsi R. The Role of Medicare Reimbursement in Determining Access to Palliative Radiotherapy During Hospice Care. JAMA Oncol. 2019;5(9):1257–1258. doi:10.1001/jamaoncol.2019.2308
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: